ALK-Abelló
158.1
DKK
+2 %
ALK B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
+2%
+6.25%
-0.63%
+0.89%
-1.43%
+20.87%
+32.75%
+61.9%
+358.26%
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.
Read moreMarket cap
35.23B DKK
Turnover
51.01M DKK
Revenue
5.54B
EBIT %
19.7 %
P/E
42.96
Dividend yield-%
-
Financial calendar
13/3
2025
General meeting '25
6/5
2025
Interim report Q1'25
21/8
2025
Interim report Q2'25
ShowingAll content types
Annual General Meeting in ALK-Abelló A/S on 13 March 2025
Annual report 2024: ALK delivers 15% sales growth with profits up 65%
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools